21.09.18: Not intended for U.S. and UK Media

Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical studies / Prophylaxis with BAY94-9027 enables sustained factor VIII concentrations in the blood over timemehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news